Stipple Bio is a Cambridge, MA-based biotechnology company developing precision cancer therapies by targeting tumor-specific cell surface epitopes. Founded in 2022 by Dr. Aaron Ring (Fred Hutch) and Dr. Aashish Manglik (UCSF), the company raised a $100M oversubscribed Series A led by RA Capital in April 2026. Its epitope-level precision approach aims to improve therapeutic index and unlock previously intractable oncology targets.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountApr 2026
Create a free account to see which investors have funded this company.
Create Free Account
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
